Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.25p -4.22% 28.375p 27.75p 29.00p 29.75p 27.25p 29.75p 1,170,684 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -32.7 -28.3 - 74.66

Motif Bio Share Discussion Threads

Showing 1426 to 1447 of 1450 messages
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
DateSubjectAuthorDiscuss
20/7/2017
15:15
Won't final results and potential FDA approval for Iclaprim be known in the first half of 2018? Maybe closer to then the share price will react more strongly?
nick rubens
20/7/2017
12:59
Big disappointment here
ilovetowin
19/7/2017
20:17
"If you want a small antibiotic company whose products have some real prospect, I'd look at Tetraphase in the US" That sounds suspiciously like a tip to me Vulgaris. See you on LSE hopefully. Ivyspivey and Dr Maccers, who seems to be on sabbatical, and used to post on here occasionally, are the relevant professionals there.
banshee
19/7/2017
19:57
I don't think I tipped them, but what I would say is that Tetraphase have some very interesting chemistry for modifying tetracyclines. They can synthesise large numbers of different molecules whereas, previously, this was difficult and slow. Their mistake, with their lead molecule, eravacycline, was an iv/oral switch trial in UTI. Patients who switched early tended to fail, the implication being that that oral wasn't giving adequate levels.... They're now doing another cUTI trial with iv only. I'll look at the LSE board.
vulgaris
19/7/2017
16:44
Ah Vulgaris, I wondered where you had got to. All the action on this one is on the LSE BB, where you could debate with other industry professionals, it is pretty much a graveyard here. Meanwhile, didn't you tip Tetraphase just before it crashed 90% or so? Or was that someone else?
banshee
19/7/2017
16:30
Banshee: apropos delafloxacin. Its merit is scope for iv to oral switch. As you note it's a fluoroquinolone; several fluoroquinolones have come unstuck post-licensing owing to rare toxicities but others (cipro- and levo-) have been highly successful. Only time will tell... HABP trials for any antibiotic are more costly than ABSSSI as harder to recruit patients..... fewer cases and more excluded owing to having already received other agents.
vulgaris
18/7/2017
13:22
REVIVE-2 has finished recruiting, so Last Patient Out should be RNS announced in a week or so. The Pacyhderm in the Pantry however, remains the potential requirement for further funding re INSPIRE.
banshee
06/7/2017
15:28
New interview with Graham Lumsden on Proactive, putting some meat onto the bones of this morning's announcement regarding the three new abstracts. http://www.proactiveinvestors.co.uk/companies/stocktube/7753/motif-bio-gearing-up-to-present-at-major-conference-on-infectious-diseases-7753.html
timbo003
04/7/2017
08:53
Anyone know when we expecting the next news update??
rizler
26/6/2017
15:48
There is a post on the LSE BB (which is host to a truly impressive quantity of wishful thinkers) saying Motif have implied informally they not going to dilute further re HABP and will only do it (ie the trial) if the "opportunity offers", that would be significant if true, although it contradicts some of their recent public statements. Additionally, in the recent past there have been posts on the LSE BB saying MOTIF have also implied that they "probably" didn't need to dilute further to complete REVIVE, a few days before they announced such a dilution. (Stand up Dr Qackers) Really they could do with this semi-mythical pharma tie up, not just because of funding HABP, but because otherwise they will have to raise another shed load of cash next year to do their own marketing. A decent such tie up would make this share the proverbial no-brainer and have the shorters (and there is a genuine semi-professional short interest here, (presumably betting on further dilution/and/or no pharma interest, since p3 failure is unlikely)), running for cover.
banshee
22/6/2017
16:22
Funding duly passed. etc....
pjj71
22/6/2017
16:20
Biotech is flying in the US... why is this as dead as a duck pond???
pjj71
22/6/2017
10:54
So we cannot sell Iclaprim in US for 5 yeas in our main indication ABSSSI? That cannot be good news surely?
adorling
20/6/2017
17:10
Because they have another set of trials INSPIRE/HABP, which were scheduled to start later this year and which were not covered by the recent raise. It is possible they may postpone them or find another way to finance them, but the situation is unclear. Pity no-one seems to have gone to the AGM the other day which might have lent some insight.
banshee
20/6/2017
17:06
Why would it fundraise again this year?
ilovetowin
20/6/2017
17:03
The 5 year exclusivity just means no-on else can market that particular antibiotic for the given indication, for that period. The class of antibiotics to which delafloxacin belongs is rather problematic to put it mildly, so not much competition for Motif. Https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm513183.htm Motif will continue to flatline till news imo, if no more fundraises this year it should at least retest 40p at some point, assuming REVIVE-2 is a pass.
banshee
20/6/2017
01:08
We need to follow the success of this new antibiotic approval by the FDA as it is for the same indication as MTFB...and it says it has a 5 year period of exclusivity for this indication??? Jun. 19, 2017 4:49 PM ET|By: Douglas W. House, SA News Editor The FDA approves privately-held Melinta Therapeutics' Baxdela (delafloxacin), a fluoroquinolone antibiotic, for the treatment of adults with acute bacterial skin and skin structure infections ((ABSSSI)). Baxdela had Qualified Infectious Disease Product (QIDP) status which provides for an additional five-year period of market exclusivity for the indication.
adorling
20/6/2017
01:07
We need to follow the success of this new antibiotic approval by the FDA as it is for the same indication as MTFB...and it says it has a 5 year period of exclusivity for this indication??? Jun. 19, 2017 4:49 PM ET|By: Douglas W. House, SA News Editor The FDA approves privately-held Melinta Therapeutics' Baxdela (delafloxacin), a fluoroquinolone antibiotic, for the treatment of adults with acute bacterial skin and skin structure infections ((ABSSSI)). Baxdela had Qualified Infectious Disease Product (QIDP) status which provides for an additional five-year period of market exclusivity for the indication.
adorling
13/6/2017
13:44
This morning's 50k buy is mine for my daughter's ISA. My 3rd "toe-dip" in the last month.
outsizeclothes.com
13/6/2017
13:19
Easy double your money here IMO. Just a bit of patience. Placing price or thereabouts is a great entry level
trotterstrading
13/6/2017
13:13
They will delay until we have much higher share price or get alternative funding for INSPIRE imo
blueblood
13/6/2017
12:35
As far as REVIVE goes it is yes, funded through to submitting the NDA, INSPIRE though is a seperate project in effect. "Graham Lumsden, CEO of Motif Bio, commented: "This financing has been well received and gives us the resources to complete the REVIVE-2 Phase 3 clinical trial and file a New Drug Application and Marketing Authorisation Application in the first half of 2018 to achieve marketing approval of iclaprim in the US and Europe. I am delighted by the support shown by our existing shareholders and also welcome a number of new institutional holders to the register."
banshee
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170721 04:51:46